Shares of Merck KGaA (OTCMKTS:MKGAF – Get Free Report) were down 3.6% during mid-day trading on Thursday . The company traded as low as $151.46 and last traded at $151.46. Approximately 77 shares changed hands during mid-day trading, a decline of 87% from the average session volume of 610 shares. The stock had previously closed at $157.0460.
Merck KGaA Trading Down 1.2%
The stock has a market capitalization of $20.05 billion, a P/E ratio of 23.69 and a beta of 0.96. The firm’s 50 day moving average price is $161.87 and its 200 day moving average price is $149.73. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.31 and a quick ratio of 0.84.
Institutional Investors Weigh In On Merck KGaA
Several institutional investors and hedge funds have recently bought and sold shares of MKGAF. Elefante Mark B purchased a new position in shares of Merck KGaA during the second quarter valued at approximately $617,000. Ames National Corp bought a new position in Merck KGaA in the 2nd quarter worth $1,009,000. Notis McConarty Edward purchased a new stake in shares of Merck KGaA in the 2nd quarter worth about $1,304,000. North Star Asset Management Inc. bought a new stake in shares of Merck KGaA during the 2nd quarter valued at about $1,411,000. Finally, Pinnacle Holdings LLC bought a new stake in shares of Merck KGaA during the 2nd quarter valued at about $1,487,000. Hedge funds and other institutional investors own 0.10% of the company’s stock.
About Merck KGaA
Merck KGaA is a Germany-based science and technology company headquartered in Darmstadt. Founded in 1668, it is one of the world’s oldest operating pharmaceutical and chemical companies. The business serves customers in more than 60 countries through three operating sectors: Healthcare, Life Science and Electronics.
The Healthcare sector develops and markets prescription medicines and specialty therapies, with activities focused on areas including oncology, neurology and immunology, fertility, and endocrinology.
See Also
- Five stocks we like better than Merck KGaA
- The Fed’s Rate Hike Could Backfire If Oil Prices Collapse
- Apple Is Quietly Building an AI Advantage Few Expected
- How Serious Is the Regulatory Threat Now Facing Tesla’s Cybercab?
- Can ServisFirst Keep Delivering?
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.
